DUBLIN--(BUSINESS WIRE)--The "Gene Therapy Market Share, Size, Trends, Industry Analysis Report, By Vector Type; By Approach; By Therapeutic Area; By Route of Administration; By Regions; Segment Forecast, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
The global gene therapy market expected to reach USD 5.02 billion by 2028, according to the study. This report gives a detailed insight into current market dynamics and provides analysis on future market growth.
The rising prevalence of chronic disorders including heredity and oncology diseases, rise in the number of clinical trials in the concerned arena, and increase in product approvals from regulatory agencies are few factors boosting the market growth. Moreover, innovations in the gene delivery systems also expedited the demand for such products.
The market is fragmented based on the therapy area, vector type, approach, route of administration, and region. In terms of therapeutic area, the market is segmented into autoimmune disorders, cardiovascular diseases, dermatological disorders, genetic disorders, hematological disorders, metabolic disorders, muscle-related diseases, oncological disorders, ophthalmic diseases, and others.
Based on the vector type, the industry is further bifurcated into viral and non-viral vectors. Based on the approach, the industry is further bifurcated into gene augmentation, oncolytic viral therapy, immunotherapy, and others. Based on the route of administration, the market is further bifurcated into intraarticular, intracerebellar, intradermal, intramuscular, intratumoral, intravenous, intravesical, intravitreal, subretinal, and others.
List of Key Players
- Dimension Therapeutics
- Novartis AG
- Bluebird Bio
- Gilead Sciences Inc.
- Human Stem Cell Institute
- Spark Therapeutics
- Celgene Corporation
- Sangamo Biosciences
- GlaxoSmithKline
- Bristol Myer's Squibb
- Celgene Corporation
Segment Highlights
- The genetic disorders segment accounted for the largest revenue share in 2020 owing to the emergence of novel disorders and associated research and innovation. Furthermore, the increasing number of genetic disorders is expected to drive segment growth.
- Based on the vector type, the viral segment accounted for over 55% in terms of revenue in 2020. This can be attributed to its high accuracy in gene delivery and the presence of several players across the market.
- North America region is dominating the global market, holding almost one-third of the market share throughout the forecast period. Positive funding scenario and the presence of competent regulatory authorities favoring the growth in the region
- The players including Novartis AG, Celgene Corporation, and Gilead Sciences Inc. together account for a significant market share of the global market in the year 2020
Key Topics Covered:
1. Introduction
2. Executive Summary
3. Research Methodology
4. Gene Therapy Market Insights
4.1. Gene Therapy - Industry snapshot
4.2. Gene Therapy Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Growing incidence of cancer and target diseases
4.2.1.2. Research and funding in gene therapy
4.2.2. Restraints and Challenges
4.2.2.1. High treatment cost
4.3. Porter's Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTLE Analysis
4.5. Gene Therapy Market Industry trends
5. Gene Therapy Market Assessment by Therapeutic Area
6. Global Gene Therapy Market, by Vector Type
7. Global Gene Therapy Market, by Approach
8. Gene Therapy Market Assessment by Route of Administration
9. Gene Therapy Market Assessment by Geography
9.1. Key findings
9.2. Introduction
9.3. Gene Therapy Market - North America
9.4. Gene Therapy Market - Europe
9.5. Gene Therapy Market - Asia-Pacific
9.6. Gene Therapy Market - Middle East & Africa
9.7. Gene Therapy Market - Latin America
10. Competitive Landscape
10.1. Expansion and Acquisition Analysis
10.1.1. Expansion
10.1.2. Acquisition
10.2. Partnerships/Collaborations/Agreements/Exhibitions
11. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/r/5diqre
